Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Several biomarkers including proteins and lipids have been reported in MS cerebrospinal fluid (CSF), reflecting different aspects of the pathophysiology particularly of relapsing-remitting MS (RRMS). Sulfatide, abundant in the myelin sheath and a proposed target for autoimmune attack in MS, has been reported altered in MS CSF. Here, we investigated the potential of CSF sulfatide and its isoforms as biomarkers in MS. A highly sensitive and quantitative mass spectrometry method was employed to determine levels of sulfatide isoforms in CSF from RRMS and progressive MS (PMS) patients, and healthy donors (HD). We demonstrate that levels of total CSF sulfatide and C24:1, C26:1, and C26:1-OH isoforms were significantly increased in PMS compared with RRMS patients and HD, while C23:0-OH was significantly decreased in CSF from PMS patients compared to the other two groups. Multivariate discriminant analysis showed that CSF sulfatide isoform pattern in PMS patients was distinct and non-overlapping with that of RRMS patients and HD. Sulfatide levels did not correlate with tested biomarkers 
method was employed to determine levels of sulfatide isoforms in CSF from RRMS and progressive MS (PMS) patients, and healthy donors (HD). We demonstrate that levels of total CSF sulfatide and C24:1, C26:1, and C26:1-OH isoforms were significantly increased in PMS compared with RRMS patients and HD, while C23:0-OH was significantly decreased in CSF from PMS patients compared to the other two groups. Multivariate discriminant analysis showed that CSF sulfatide isoform pattern in PMS patients was distinct and non-overlapping with that of RRMS patients and HD. Sulfatide levels did not correlate with tested biomarkers MS is a chronic inflammatory disease of the central nervous system (CNS) where the myelin sheath around nerve fibers is the target of an autoimmune attack. This leads to demyelination, axonal loss, and subsequent progressive neurologic functional deficits (Steinman 2014 ). There are two major phenotypes of MS, relapsing-remitting (RRMS) with relapses mediated by inflammatory activity, and progressive MS (PMS) characterized by slowly evolving disability that exhibits degenerative features. PMS in turn can be divided into primary progressive MS (PPMS), if the clinical course is progressive from onset, or secondary progressive MS (SPMS), when RRMS subsequently transforms into a progressive state (Steinman 2014) . With few exceptions, the diseasemodifying therapies of MS are approved for RRMS and not PMS, whereas biomarkers may reflect inflammatory activity as well as degeneration. The distinction between MS phenotypes is essentially based on clinical grounds. Although proteomics and metabolomics technologies could differentiate phenotypes of MS (Teunissen et al. 2011; Dickens et al. 2014) , there is to the best of our knowledge, no biomarker from body fluids that can convincingly differentiate between RRMS and PMS. In fact, increased biomarkers of inflammation and degeneration are not confined to RRMS but are also found in active PMS (Sellebjerg et al. 2017) .
Sulfatide is a sulfated glycosphingolipid found at high concentrations in the myelin sheath. Over 70% of the myelin sheath is comprised of lipids, and around 30% of myelin lipids are sulfatide and its non-sulfated precursor galactosylceramide (Norton and Cammer 1984) . Sulfatide consists of a mixture of naturally existing isoforms with different physicochemical properties. The composition of sulfatide differs between organs, where the predominant isoforms in myelin are characterized by long-chain fatty acids (C22-C26 carbon atoms) (Pintado-Sierra et al. 2017 ). An increasing number of reports suggest that lipids are targeted in MS autoimmunity (Dendrou et al. 2015) . In particular, enhanced antibody response to sulfatide has been closely associated with CNS inflammation and demyelination (Halder et al. 2007 , Kanter et al. 2006 , and altered levels of sulfatide and anti-sulfatide antibody were not only found in patients with neurodegenerative disorders (Dali et al. 2015) but also in MS (Ilyas et al. 2003 , Moyano et al. 2013 , Haghighi et al. 2012 . In addition, it was demonstrated that MS patients harbor an increased frequency of glycolipid-reactive T cells in peripheral blood compared to healthy individuals (Shamshiev et al. 1999) .
Myelin-associated isoforms of sulfatide act as endogenous antigens recognized by a subset of T lymphocytes in the context of the major histocompatibility complex class I-like molecule, CD1d (Jahng et al. 2004; Zajonc et al. 2005; Blomqvist et al. 2009; Bai et al. 2012; Girardi et al. 2012) . Moreover, sulfatide-reactive T lymphocytes are involved in the pathogenesis of autoimmune encephalomyelitis, the mouse model for MS (Jahng et al. 2004) . Recently, we reported that Vd1 + T lymphocytes, a subset of cd T lymphocytes that include sulfatide-reactive, CD1d-restricted T cells (Bai et al. 2012; Luoma et al. 2013) , have increased interferon (IFN)-c production in newly diagnosed RRMS patients, suggesting that they may be involved in the early stage of the immunopathogenesis of MS (Singh et al. 2017) . Sulfatide can also modulate inflammation independently of CD1d (Jeon et al. 2008; Mycko et al. 2014) .
Despite the abundance of myelin-associated sulfatide and its proposed roles in the pathogenesis of several CNS disorders, most studies on antigen targets in MS have focused on the myelin proteins. Previous publications suggest that during the autoimmune destruction of CNS myelin, sulfatide may be released and appear in elevated concentrations in cerebrospinal fluid (CSF) (Haghighi et al. 2012) . This could lead to increased activation of sulfatidereactive T lymphocytes that may contribute to the autoimmune process. Furthermore, CNS inflammation and degeneration could lead to alterations of the composition of sulfatide isoforms in CSF, making it a possible marker of the disease process and MS phenotypes.
In this study, we have used a recently developed method, based on highly sensitive ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) (Blomqvist et al. 2017) , to investigate the concentrations of sulfatide isoforms in CSF from newly diagnosed RRMS and PMS patients and compared them to CSF obtained from healthy donors (HD).
Materials and methods

Study groups
All patients (n = 42) fulfilled the revised McDonald diagnostic criteria of MS (Polman et al. 2011) . They were consecutively enrolled in the study at the MS center of Sahlgrenska University Hospital, Gothenburg, Sweden, and included newly diagnosed RRMS (n = 29) and PMS (n = 13; 6 PPMS and 7 SPMS). Inclusion criteria were confirmed RRMS or PMS patients with no concomitant neurological disease and subjects were treatment na€ ıve or no IFN-b and/or glatiramer acetate treatment within 12 months from study baseline. Subjects who had other neurological disease or disorders, current disease-modifying treatment, previous treatment with other disease-modifying therapies than IFN-b and/or glatiramer acetate, and corticosteroid treatment within 3 months from baseline were excluded from the study. All MS patients were examined and their neurological disability was scored according to the Expanded Disability Status Scale (EDSS) (Kurtzke 1983) at the time of sampling. HD (n = 16; 5 males and 11 females; range 24-50 years; mean AE SEM 32.6 AE 1.8), age-matched with RRMS patients, served as controls. None of the HD had any neurological signs or a history of neurological disease. No statistical methods were used to predetermine sample sizes. Demographics and clinical characteristics of patients are shown in Table 1 . None of the patients were on disease-modifying drugs, and thus the study was not pre-registered.
All patients and HD provided written informed consent and the Regional Ethics Committee of Gothenburg approved the study (T487-14).
Sample preparation
The spinal tap and the CSF samples were handled according to the consensus protocol of the BioMS-EU network for CSF biomarker research in MS (Teunissen et al. 2009 ). Venous blood samples from patients were collected in heparinized tubes. Blood was diluted 1 : 1 with sterile phosphate-buffered saline (pH 7.2). Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation using Ficoll-Paque (density: 1.077 g/mL; Cat# 17-1440-03; GE Healthcare, Uppsala, Sweden). Cell viability was determined by Trypan Blue (Cat# 15-250-061; Gibco, Rockville, MD, USA) dye exclusion. CSF samples were collected in 10 mL polypropylene tubes (Cat# 62.9924.284; Sarstedt) and centrifuged (400 g for 10 min at 4°C); cell-free CSF samples were immediately stored at À80°C in 0.5 mL aliquots for future analyses.
CSF sulfatide level detection
The quantification of sulfatide isoforms was performed as previously described (Blomqvist et al. 2017) . No blinding of the samples was performed, however, the sample preparation and analysis of sulfatides were performed after simple randomization of samples. Briefly, sulfatides were automatically extracted from 100 lL CSF using the robot-assisted butanol:methanol (BUME) method (Lofgren et al. 2012) and further quantified by UPLC-MS/MS. (Blomqvist et al. 2017) . Sulfatide C19:0 isoform was used as an internal standard and quantification was made using a native sulfatide mixture with known total sulfatide content and isoform composition.
Neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) analyses Neurofilament light chain (NFL) concentration in CSF was measured with a sensitive sandwich enzyme-linked immunosorbent assay (ELISA) (NF-light â ELISA kit, UmanDiagnostics AB, Ume a, Sweden). Intra-and inter-assay coefficients of variation were below 10%. The lower limit of quantification of the assay was 31 pg/mL. The glial fibrillary acidic protein (GFAP) concentration was measured by ELISA as previously described (Rosengren et al. 1994) . The absorbance was read at 490 nm, and the sensitivity of the GFAP assay was 16 pg/mL. Both assays were conducted at the Clinical Neurochemistry Laboratory (Sahlgrenska University Hospital) according to protocols approved by the Swedish Board for Accreditation and Conformity Assessment.
Magnetic resonance imaging (MRI)
MRI scans of brain and cervical column were performed with 3.0 Tesla machine, using a 3 mm thicknesses. A standard protocol for MS was used with 3D T1-weighted sequence following a dose of intravenous gadolinium (Gd) contrast, T2-weighted sequence, and 3D fluid-attenuated inversion recovery sequence according to Swedish MS guidelines (Vagberg et al. 2017) . The number of T2-weighed and contrast-enhancing T1 lesions were recorded (Table 1) . Synthetic MRI (SyMRI) was used to assess brain atrophy with automatic quantification of brain parenchymal fraction (BPF). SyMRI is a novel, reproducible, and fast automatic method for calculating BPF, correlates strongly with a manual segmentation and has a low coefficient of variation (0.45%) (Vagberg et al. 2013) .
PBMC stimulation and flow cytometry of T-cell receptor (TCR) Vd1 + IFN-c + cells
To stain for the intracellular cytokine IFN-c, PBMC were stimulated with phorbol 12-myristate 13-acetate (50 ng/mL) and ionomycin (500 ng/mL) (Sigma-Aldrich, Saint Louis, MO, USA) in the presence of Brefeldin A (Cat# 00-4506-51; eBioscience, San Diego, CA, USA) for 4 h at 37°C, as described before (Singh et al. 2017 
Statistical analysis
A Gaussian distribution was assessed using D'Agostino and Pearson omnibus normality test. CSF sulfatide levels were compared between HD, RRMS, and PMS using one-way ANOVA with Tukey's post hoc multiple comparisons or Kruskal-Wallis test with Dunn's post hoc multiple comparisons, for Gaussian or non-Gaussian distributions, respectively. Correlation analyses were performed using Spearman's non-parametric correlation. The receiver-operating curve estimation was performed assuming the non-parametric distribution. Sensitivity and specificity was calculated using Youden index (calculated as sensitivity + specificity À1), which calculates optimal cutoffs that maximize both sensitivity and specificity. A test for outliers was not performed. Results are presented as mean AE standard error of mean (SEM), and a two-sided p-value < 0.05 was considered to be statistically significant. All statistical tests were performed using GraphPad Prism Software, version 7 (La Jolla, CA, USA).
Multivariate discriminant analysis Discriminant analysis of principal components (DAPC) was used to describe the between-group diversity of sulfatide isoform levels. For this analysis the two isoforms with lowest concentration in CSF (C26:0-OH and C26:1-OH) were omitted. DAPC is comprised of a principal component analysis and a linear discriminant analysis (Jombart et al. 2010) . The number of principal components to retain was assessed by repeated (n = 30) cross-validation (training set = 80%). The number of principal components that produced the highest mean success was used in further analyses. DAPC was performed using statistical computing software R (version 3.4.2) with package adegenet (version 2.1.0) (Jombart and Ahmed 2011) .
Results
PMS patients had increased levels of sulfatide isoforms in CSF compared to RRMS patients and HD Here, we have investigated the levels of sulfatide isoforms in CSF from HD and patients with newly diagnosed RRMS or PMS. Using UPLC-MS/MS, we identified 20 different sulfatide isoforms in CSF that were compared between the three groups ( Fig. 1 and Figure S1 ). As shown before (Blomqvist et al. 2017) , the sulfatide isoforms carried a range of fatty acids, varying in chain length, hydroxylation, and degree of unsaturation. The total sulfatide levels in CSF from PMS patients were significantly higher compared with those determined in CSF from RRMS patients (97.8 AE 9.6 vs. 77.4 AE 3.8 nM; p = 0.044). However, there were no significant differences observed between PMS patients and HD (p = 0.30), nor between RRMS patients and HD (p = 0.67) (Fig. 1a) . The HD were age-matched with RRMS patients, while the age of PMS patients was slightly higher than that of the other two groups (see Materials and methods and Table 1 ). We exclude age as a determinant of sulfatide levels in CSF as we have previously shown, employing a cohort of HD with a broader age range, that sulfatide levels in CSF do not increase with age (Blomqvist et al. 2017) . The comparison of individual isoforms of sulfatide in CSF showed that in all groups, C24:1 was the most abundant isoform, in agreement with previous studies (Blomqvist et al. 2017) which were also in line with findings in adult brain (Svennerholm and Stallberg-Stenhagen 1968; Hsu et al. 1998) . C24:1 together with C26:1 and C26:1-OH were found to be the statistically most significantly increased isoforms in CSF from PMS patients compared with CSF from HD and RRMS patients ( Fig. 1 B and Figure S1 ). In contrast, one of the isoforms, C23.0-OH, was reduced in CSF of PMS patients compared with the other two groups (Fig. 1b) . Relapse within 3 weeks or 3 months before sampling from RRMS patients did not affect levels of CSF sulfatides shown in Fig. 1 (data  not shown) . The levels of the other sulfatide isoforms identified in CSF did not differ significantly between the HD, RRMS, and PMS groups ( Figure S1 ). There were neither significant difference between CSF levels of total sulfatide nor of the specific isoforms when comparing PPMS to SPMS patients ( Figure S2 ). To evaluate the utility of sulfatides in CSF as biomarkers, we constructed receiver-operating curve curves (Fig. 2) . The largest area under the curve (AUC) was obtained with sulfatide C26:1 when comparing PMS with the other two groups (PMS vs. HD: AUC 0.87, CI 0.72-1.015, 85% sensitivity and 87% specificity; PMS vs. RRMS: AUC 0.86, CI 0.72-1.01, 85% sensitivity and 86% specificity).
The global isoform pattern of sulfatide in CSF distinguished PMS patients from RRMS patients and HD We next performed multivariate discriminant analysis, taking into account the variance of the different isoforms of sulfatide in CSF, to obtain a global comparison of isoforms in CSF between HD and the two major phenotypes of MS. We found that retaining eight principal components was enough to produce a clear separation in this case. In a combined analysis of all three groups, we observed that PMS patients were distinct from the other two groups in terms of their sulfatide isoform distribution in CSF, while the pattern for RRMS patients and HD largely overlapped. This is displayed in a one-dimensional plot in Fig. 3a and in a two-dimensional plot in Fig. 3b . The values from all PMS patients fall in an area that is clearly separated and not overlapping with values from RRMS and HD (Fig. 3b) . As shown in inlet in Fig. 3b , the discriminant analysis was dominated by one eigenvalue and therefore, one dimension should be sufficient to separate groups (as seen in Fig. 3a) . To investigate whether there was an underlying difference between RRMS and HD, not revealed in the comparison of all three groups, we performed a separate analysis of only the RRMS and HD groups. The result shows that RRMS and HD values were overlapping also in this analysis (not shown). Taken together, these observations suggest that the sulfatide isoform pattern in CSF can discriminate PMS from RRMS.
Sulfatide levels in CSF did not correlate with frequencies of IFN-c-producing Vd1 T lymphocytes Vd1 + T lymphocytes can recognize sulfatide presented on CD1d (Luoma et al. 2013 ) and may be involved in the early phase of the immunopathogenesis of RRMS (Singh et al. 2017) . Furthermore, the CSF carries antigens that activate immune cells. Therefore, we postulated that a high level of sulfatide in CSF might contribute to the increased activation of Vd1 + T cells in RRMS patients. We did not investigate Vd1 + T cells in PMS, as this disease state is primarily characterized by neurodegeneration rather than autoimmunity. However, our analysis did not reveal a positive correlation between frequencies of IFN-c-producing Vd1 + T lymphocytes and levels of total sulfatide in CSF, nor with the levels of individual isoforms C24:1 and C26:1 (Fig. 4a and Figure S3A ). 
No correlation of CSF sulfatide with other CSF biomarkers, MRI measures, and disability in MS patients
Previous studies have demonstrated that MS is associated with increased levels in the CSF of CNS-derived proteins such as NFL and GFAP (Malmestrom et al. 2003) . NFL is considered a marker for axonal damage, while GFAP is a marker for astrogliosis. As confirmed in this study (Table 1) , NFL is elevated in both RRMS and PMS compared with HD. Similarly, GFAP is increased in RRMS, but even more so in PMS (Table 1) (Malmestrom et al. 2003) . In order to further explore the association of altered CSF isoforms of sulfatide with established disease parameters in MS, we performed correlation analysis between levels of total sulfatide or selected isoforms and other CSF biomarkers, MRI outcomes, and clinical measures. However, no significant relationships were found between CSF concentrations of sulfatides and GFAP or NFL, the numbers of T2 or contrast-enhancing T1 lesions, the BPF as measure of brain volume on SyMRI, nor with the EDSS score of RRMS patients or PMS patients (Fig. 4b, c and Figure S3A , B and data not shown). 
Discussion
Sulfatide is a major glycosphingolipid of the myelin sheath, which is the target of autoimmune destruction in MS. Different isoform profiles of sulfatide and other glycosphingolipids are formed by specific cells and organs, and most likely have individual biological functions, and are altered in different disease states. We therefore hypothesized that isoforms of sulfatides might be altered in the pathogenesis of MS and that such alterations would be reflected in the CSF and provide potential biomarkers of disease. To investigate this, we applied a newly developed methodology (Blomqvist et al. 2017) to analyze a wide range of sulfatides in CSF from MS patients. We find an elevated level of total sulfatides in CSF from PMS patients compared with RRMS patients, and highly significant changes in specific isoforms in PMS patients compared to both RRMS and HD. In contrast, there was no difference in total sulfatide levels or sulfatide isoform composition in CSF from RRMS patients compared with HD. However, the values overlap to a large extent between the three groups preventing classification to one of the groups based on a single measurement. Importantly, however, we demonstrate that discriminant analysis of principal components of sulfatide isoforms in CSF Fig. 4 CSF sulfatide levels did not correlate with disease biomarkers or clinical parameters. Correlation analyses between the CSF sulfatide and IFN-c production in Vd1 cells from peripheral blood in relapsingremitting MS (RRMS) patients (n = 15) are shown (a). Total sulfatide levels in CSF from RRMS (n = 29) (b) and progressive MS (PMS) (n = 13) (c) patients is correlated with CSF biomarkers GFAP and NFL, and clinical parameters MRI (Gd) and EDSS. NFL, neurofilament light chain; GFAP, glial fibrillary acidic protein; EDSS, Expanded Disability Status Scale. r is Spearman's correlation coefficient. distinguished PMS patients from RRMS patients with newly diagnosed disease. This analysis provided a complete separation of values obtained for PMS patients compared with the two other groups, while values from RRMS patients and HD overlapped. This is, to the best of our knowledge, the first convincing biomarker from a body fluid that appears to differentiate, on the individual patient level, patients with PMS and RRMS.
We previously reported elevated levels of total sulfatide in CSF from MS patients with established disease (Haghighi et al. 2012) . The patient cohort in the previous study included an equal number of RRMS and PMS patients with a mean duration of disease of 16 years (14 years for the RRMS patients). In contrast, the data presented here are from newly diagnosed RRMS patients (mean disease duration of 2.3 years) in one group, and PMS patients (mean disease duration of 13.8 years) in a separate group. Together with the results in the previous study, this may suggest that longer disease duration with involvement of CNS degeneration in RRMS can lead to increased sulfatide levels in CSF, and that altered sulfatide composition in CSF might precede RRMS conversion to PMS. It will be important to validate these results with a larger cohort of patients, and further, to perform longitudinal studies to determine whether the altered distribution of sulfatide isoforms, as seen here in CSF from PMS patients, precedes the conversion of RRMS to secondary PMS. If that is the case, the composition of sulfatide isoforms in CSF should be evaluated as a prognostic biomarker for risk and/or timing of conversion of RRMS to SPMS.
To determine whether sulfatide levels in CSF were associated with CSF biomarkers of MS disease or clinical manifestations that indicate certain aspects of disease pathogenesis, we performed correlation analyses. However, sulfatide levels (total and selected isoforms) in CSF of MS patients did not correlate with degenerative CSF biomarkers in RRMS or PMS disease, that is, NFL indicating axonal damage and GFAP, a marker of astrocyte damage and astrogliosis. Nor was there a correlation with MRI measures such as T2 contrast-enhancing lesions and brain volume, or with clinical assessment of neurological disability, (EDSS score). Thus, these data suggest that CSF sulfatide level and isoform alteration are not markers of disease activity, nor supports the concept that sulfatide is associated with degeneration in PMS or newly diagnosed RRMS patients. A previous study analyzed four different sulfatide isoforms in serum of RRMS patients (Moyano et al. 2013) . Interestingly, the serum level of C18:0 and C24:1 sulfatide isoforms correlated with disease status in RRMS patients. An analysis of a broader panel of sulfatide isoforms in serum of MS patients is therefore warranted.
Our in-depth analysis of a broad array of sulfatide isoforms revealed a very distinct pattern of changes in the CSF concentration-specific sulfatide isoforms in PMS patients compared with RRMS and HD. It is notable that a patient cohort with Alzheimer's disease demonstrated unaltered total levels of sulfatides in CSF, while compared to the control group, the ratio of hydroxylated to non-hydroxylated sulfatides was significantly increased in patients (Blomqvist et al. 2017) . This change was suggested to reflect gray matter pathology in Alzheimer's disease since sulfatide in gray matter has been shown to contain high proportions of hydroxylated sulfatide isoforms (Yuki et al. 2011) . This pattern is different from what we find in CSF from PMS patients, indicating disease-specific alterations in sulfatide isoform composition. Sulfatide in the CNS is mainly produced by oligodendrocytes, and myelin is the major source of sulfatide, however, the origin of sulfatide in CSF is not well understood. Furthermore, the sulfatide fatty acid composition differs when comparing myelin-associated sulfatide enriched in very long-chain fatty acids (C22-C26-sulfatide) with neurons and astrocytes where large amounts of C18:0-sulfatide are present (Isaac et al. 2006) . Altered composition of CSF sulfatide in neurodegenerative diseases could potentially have different origins, including a modified sulfatide biogenesis induced by the pathological process, or disease-induced release into CSF of sulfatides with tissue/ cell-specific sulfatide isoform composition. It was recently shown that sulfatides with shorter fatty acid chains (C16/ C18) were produced by pro-oligodendroblast in early embryonic development, while longer fatty acid chains appeared later in oligodendrocyte development with the C24 chain dominating in the adult brain (Hirahara et al. 2017) . The alterations we find in CSF of PMS patients are all of sulfatides with longer fatty acid chains (C23-C26). Thus, these changes are not consistent with the predominant isoforms that occur during developmental myelination (Hirahara et al. 2017) , or remyelination in MS involving oligodendrocyte progenitor cells. There are several studies that establish or suggest the biological importance of different isoforms of sulfatides and other glycosphingolipids in various cells/tissues including myelin (Buschard et al. 2006; Edvardson et al. 2008; Blomqvist et al. 2009; van Zyl et al. 2010; Subramanian et al. 2012; Park et al. 2014; Schmitt et al. 2015; Hirahara et al. 2017; Saroha et al. 2017) . While sulfatides with longer fatty acids are important for the stability and maintenance of the myelin sheath (Schmitt et al. 2015) , the function of distinct isoforms, such as C24:1, C26:1, and C23:0-OH, is not known. It is therefore unclear what role the changes observed in our study might have in MS disease pathogenesis. Further studies are warranted to identify the underlying processes that determine pathological changes of sulfatide isoform composition in CSF and their relevance for disease. A recent report demonstrates that there is also an increase in sphingomyelin and hexocylceramide in CSF in MS and suggests hexocylceramides as markers of worsening disability in MS (Checa et al. 2015) . Thus, it might be of value to apply a broader approach to investigate the potential of sphingolipids and their isoforms as biomarkers for MS progression.
The CSF is a source of antigens that are targets of immune reactivity in RRMS. With the lack of an identified lymphatic system draining CNS, it was until recently unclear how CNS antigens were delivered to lymph nodes and antigenpresenting cells that initiate immune reactivity. A meningeal lymphatic system has now been demonstrated that drains the CNS to the deep cervical lymph nodes, possibly via CSF (Aspelund et al. 2015; Louveau et al. 2015) . We reasoned that destruction of myelin during MS might increase sulfatide concentration in CSF, which could drain to lymph nodes and contribute to the increased immune reactivity to sulfatide seen in RRMS. However, concentration and composition of sulfatide in CSF from newly diagnosed RRMS patients were not different from that of HD. It is still possible that sulfatide from degraded myelin is transported to draining lymph nodes by antigen-presenting cells, and/or presented to T lymphocytes by local antigen-presenting cells in the CNS.
To the best of our knowledge, this is the first study to demonstrate that a body fluid biomarker, the isoform composition of CSF sulfatides, can discriminate on the individual patient level between different phenotypes of MS. Further studies are encouraged to assess whether alterations of CSF sulfatide composition occurs in remyelinated nerve fibers and precedes the conversion of RRMS to PMS, and the potential significance of such measurement as a biomarker for disease progression in MS.
Supporting information
Additional Supporting Information may be found online in the Supporting Information section at the end of the article: Figure S1 . Altered levels of individual isoforms of sulfatide in CSF from HD and patients with RRMS or PMS. A comparison of average concentrations of 20 different CSF sulfatide isoforms in CSF from HD (n=16), RRMS (n=29), and PMS (n=13) patients is shown. Isoforms with hydroxylated fatty acids are plotted to the right. Sulfatides that show significant difference between PMS and the other two groups are shown in bold. nM, nanomolar. Figure S2 . Comparable sulfatide levels in CSF from PPMS and SPMS patients. The levels of total CSF sulfatide (A) and indicated isoforms (B) were compared between PPMS (n=6) and SPMS (n=7) patients. PPMS, primary progressive MS; SPMS, secondary progressive MS; nM, nanomolar. Indicated p-values were derived using the Mann-Whitney test (two-tailed). Figure S3 . CSF levels of sulfatide isoforms did not correlate with disease biomarkers or clinical parameters. Correlation analyses between the CSF sulfatide isoforms and IFN-© production in V TM 1 cells from peripheral blood, CSF biomarkers GFAP and NFL, and clinical parameters MRI (Gd) and EDSS in RRMS (n=29) patients (A) and PMS (n=13) (B) are shown. NFL, neurofilament light chain; GFAP, glial fibrillary acidic protein; EDSS, Expanded Disability Status Scale. r is Spearman's correlation coefficient.
